Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer

Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer

Abstract Background Novel human epidermal growth factor receptor 2 (HER2)-directed antibody–drug conjugates prompt the identification of the HER2-low subtype. However, the biological significance of HER2-low expression in breast cancer is unclear. Methods Clinical and genomic data of 579 metastatic...

Full description

Bibliographic Details
Main Authors:	Juan Jin, Bin Li, Jianing Cao, Ting Li, Jian Zhang, Jun Cao, Mingchuan Zhao, Leiping Wang, Biyun Wang, Zhonghua Tao, Xichun Hu
Format:	Article
Language:	English
Published:	BMC 2023-06-01
Series:	Journal of Translational Medicine
Subjects:	HER2-low breast cancer Antibody–drug conjugates HER2 expression HER2 dynamics Metastatic breast cancer Heterogeneity
Online Access:	https://doi.org/10.1186/s12967-023-04076-9

Similar Items

Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
by: Heidi Ko, et al.
Published: (2023-11-01)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
by: Mengyuan Cai, et al.
Published: (2023-07-01)

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
by: Simon Peter Gampenrieder, et al.
Published: (2021-12-01)

Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer
by: Huina Zhang, et al.
Published: (2022-12-01)

Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)
by: Bu Hong, et al.
Published: (2023-12-01)

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
by: Elie Rassy, et al.
Published: (2022-12-01)

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
by: Emanuela Ferraro, et al.
Published: (2021-08-01)

A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China
by: Shuling Zhou, et al.
Published: (2023-01-01)

A Novel Small Molecular Antibody, HER2-Nanobody, Inhibits Tumor Proliferation in HER2-Positive Breast Cancer Cells In Vitro and In Vivo
by: Yan Yan, et al.
Published: (2021-05-01)

Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
by: Lin-Yu Xia, et al.
Published: (2024-04-01)

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas
by: Enrico Berrino, et al.
Published: (2022-08-01)

First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study
by: Meryem Aitelhaj, et al.
Published: (2016-08-01)

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
by: Chan Arlene, et al.
Published: (2012-11-01)

Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer
by: Eliya Farah, et al.
Published: (2024-01-01)

Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer
by: Minghui Yu, et al.
Published: (2023-03-01)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
by: Konstantinos Venetis, et al.
Published: (2022-03-01)

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
by: Yuxin Mu, et al.
Published: (2023-12-01)

Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions
by: Heng-Zhou Lai, et al.
Published: (2022-08-01)

Frequency of HER-2 over Expression in the Patients with Breast Cancer after Mastectomy
by: S kargar, et al.
Published: (2013-10-01)

Male HER-2 positive metastatic breast cancer: A case report
by: Na Lin, et al.
Published: (2020-12-01)

Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature
by: Jennifer Y. Ge, et al.
Published: (2021-07-01)

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-05-01)

Real-world data of HER2-low metastatic breast cancer: A population based cohort study
by: Emily I. Holthuis, et al.
Published: (2022-12-01)

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs
by: Tejaswini P. Reddy, et al.
Published: (2020-05-01)

HER2-positive breast cancer – Available anti-HER2 therapies and new agents under investigation
by: Martyna Zielińska, et al.
Published: (2020-06-01)

Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
by: Paolo Tarantino, et al.
Published: (2021-04-01)

Real-world experience with trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and HER2-positive gastric cancer: A retrospective study
by: Vladimir I. Evdokimov, et al.
Published: (2023-12-01)

How I treat HER2-low advanced breast cancer
by: Ilana Schlam, et al.
Published: (2023-02-01)

Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs
by: Manuel Gámez-Chiachio, et al.
Published: (2022-09-01)

Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications
by: Ana Godoy-Ortiz, et al.
Published: (2019-10-01)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
by: Diana B. Peckys, et al.
Published: (2021-11-01)

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy
by: Page E. Blas, et al.
Published: (2024-03-01)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
by: Laura L. Michel, et al.
Published: (2020-10-01)

The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions
by: Saleh Alrhmoun, et al.
Published: (2022-12-01)

Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer
by: M. A. Frolova, et al.
Published: (2021-12-01)

Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer
by: Santiago Terán, et al.
Published: (2023-10-01)

Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
by: Yu Y, et al.
Published: (2022-12-01)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
by: Bin Shao, et al.
Published: (2022-08-01)

Survival analysis of palliative radiotherapy in patients with HER-2+ metastatic breast cancer
by: Xueting Li, et al.
Published: (2024-01-01)